Gilead Sciences Aktie News

FOSTER CITY, Calif.--(BUSINESS WIRE)--Gilead Sciences, Inc. (Nasdaq: GILD) today announced an agreement with the U.S. government designed to reduce drug costs for Americans, reinforcing the company's long-standing commitment to U.S.-based innovation, affordability, and global health leadership. “This agreement reflects a foundational commitment to both affordability and future innovation, a com...

The White House is getting ready to announce more deals with drugmakers aimed at lowering drug prices.

FOSTER CITY, Calif.--(BUSINESS WIRE)--Gilead Sciences, Inc. (Nasdaq: GILD) announced today that Keeley Wettan will be appointed Executive Vice President, General Counsel, Legal & Compliance effective immediately. She will join the company's senior leadership team and report to Chairman and Chief Executive Officer Daniel O'Day. Ms. Wettan has held increasingly senior legal leadership roles withi...

Inflation, interest rates, and broader economic uncertainty have forced companies across many sectors to prioritize efficiency. In this environment, it can be particularly challenging for firms to maintain cash flow, which is vital to their continued healthy operations and growth.

Gilead Sciences said on Monday its experimental HIV treatment met the main goal in a late-stage trial.

FOSTER CITY, Calif.--(BUSINESS WIRE)--Gilead Sciences, Inc. (Nasdaq: GILD) today announced positive topline results from the Phase 3 ARTISTRY-2 trial. The double-blind trial evaluated the treatment responses of adults with HIV who are virologically suppressed switching from BIKTARVY® (bictegravir 50 mg/emtricitabine 200 mg/tenofovir alafenamide 25 mg tablets, B/F/TAF) to a fixed-dose combinatio...

Gilead Sciences and Arcus Biosciences said on Friday they would stop a late-stage study testing their experimental cancer drug combination in patients with advanced stomach and esophageal cancers after it failed to show a survival benefit.

FOSTER CITY, Calif.--(BUSINESS WIRE)--Gilead Foundation awards $3M in grants to close gaps in education, care, and support for people living with metastatic breast cancer.